Assessing the clinical benefit of systemic adjuvant therapies for early breast cancer
- Alternative title
-
Bestimmung des klinischen Nutzens systemischer adjuvanter Therapien beim frühen Mammakarzinom
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Geburtshilfe und Frauenheilkunde, 77.2017, Nr. 10, S. 1079–1087, doi:10.1055/s-0043-119542
- Keyword
-
Krebs
Onkologie
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (who)
-
Universitätsbibliothek Johann Christian Senckenberg
- (when)
-
2017
- Creator
- URN
-
urn:nbn:de:hebis:30:3-442927
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:49 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Möbus, Volker
- Hell, Susanne
- Schmidt, Marcus
- Universitätsbibliothek Johann Christian Senckenberg
Time of origin
- 2017
Other Objects (12)
Adjuvant therapies of cancer
Adjuvant therapies and markers of post-surgical minimal residual disease, 2.. Adjuvant therapies of the various primary tumors
Adjuvant therapy of primary breast cancer
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
The influence of radio-immunotherapy on the tumor microenvironment of breast-to-brain metastasis and the investigation of novel adjuvant therapies
Adjuvant therapy of breast cancer IV : with 71 tables
Adjuvant therapy of breast cancer V : with 71 tables
Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry
Adjuvant therapy of primary breast cancer VI : with 60 tables
Update breast cancer 2023 Part 3 – expert opinions of early stage breast cancer therapies
Update breast cancer 2023 part 3: expert opinions of early stage breast cancer therapies
Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases
Adjuvant therapies of cancer
Adjuvant therapies and markers of post-surgical minimal residual disease, 2.. Adjuvant therapies of the various primary tumors
Adjuvant therapy of primary breast cancer
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
The influence of radio-immunotherapy on the tumor microenvironment of breast-to-brain metastasis and the investigation of novel adjuvant therapies
Adjuvant therapy of breast cancer IV : with 71 tables
Adjuvant therapy of breast cancer V : with 71 tables
Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry
Adjuvant therapy of primary breast cancer VI : with 60 tables
Update breast cancer 2023 Part 3 – expert opinions of early stage breast cancer therapies
Update breast cancer 2023 part 3: expert opinions of early stage breast cancer therapies
Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases
Adjuvant therapies of cancer
Adjuvant therapies and markers of post-surgical minimal residual disease, 2.. Adjuvant therapies of the various primary tumors
Adjuvant therapy of primary breast cancer
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
The influence of radio-immunotherapy on the tumor microenvironment of breast-to-brain metastasis and the investigation of novel adjuvant therapies
Adjuvant therapy of breast cancer IV : with 71 tables
Adjuvant therapy of breast cancer V : with 71 tables
Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry
Adjuvant therapy of primary breast cancer VI : with 60 tables
Update breast cancer 2023 Part 3 – expert opinions of early stage breast cancer therapies
Update breast cancer 2023 part 3: expert opinions of early stage breast cancer therapies